Business Context and Reporting Period
Company: Sanara Medtech Inc. (SMTI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 29, 2026
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with MiMedx Group, Inc. ("Parent").
Sanara Medtech Inc. has agreed to be acquired by MiMedx Group, Inc. Upon consummation, Sanara will become a wholly-owned subsidiary of MiMedx. The Sanara Board of Directors unanimously approved the transaction and recommended it to stockholders.
Key Financial Metrics and Transaction Terms
This filing details the terms of the proposed merger rather than historical financial performance. Key financial terms include:
- Merger Consideration: Each outstanding share of Sanara Common Stock will be converted into:
- Cash: $33.00 per share.
- Stock: 0.4735 shares of MiMedx Common Stock (valued at $2.00 per share based on a 5-day average closing price prior to July 29, 2026).
- Total Consideration Value: Approximately $35.00 per share ($33.00 cash + $2.00 stock).
- Termination Fees:
- Parent Termination Fee: $22,540,785.00 payable by Sanara to MiMedx under specific conditions (e.g., Superior Proposal, Adverse Recommendation Change).
- Company Termination Fee: $9,660,336.00 payable by MiMedx to Sanara if MiMedx fails to consummate the merger when required.
- Equity Awards: Restricted stock and options will be converted into cash and MiMedx stock equivalents based on the merger consideration.
Note: The filing text does not provide specific values for Sanara's historical revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Conditions
The primary material change is the initiation of the acquisition process. The transaction is subject to several closing conditions, including:
- Approval by a majority of Sanara stockholders.
- Expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of other regulatory approvals.
- Effectiveness of the Form S-4 registration statement and listing approval of MiMedx stock on Nasdaq.
- Absence of a Material Adverse Effect since the agreement date.
- Accuracy of representations and warranties.
Voting Agreement: Certain stockholders holding approximately 38.9% of Sanara's voting power have entered into a voting agreement to support the merger and oppose alternative proposals.
Outlook, Risks, and Contingencies
Outlook: The transaction is expected to close subject to the satisfaction of conditions. If consummated, Sanara stock will be delisted from the Nasdaq Capital Market.
Risks and Contingencies:
- Regulatory Approval: Failure to obtain necessary antitrust or foreign direct investment approvals could delay or terminate the deal.
- Stockholder Approval: The deal requires affirmative vote by Sanara stockholders.
- Superior Proposals: Sanara may terminate the agreement to pursue a "Superior Proposal" if fiduciary duties require it, subject to paying the termination fee.
- Operational Disruption: Risks include distraction of management, retention of key personnel, and integration challenges.
- Market Conditions: Adverse economic or industry conditions could impact the transaction.
Investor Verification Checklist
- Verify the final approval status of the merger by Sanara stockholders.
- Monitor the status of regulatory approvals, specifically under the Hart-Scott-Rodino Act.
- Review the definitive Proxy Statement/Prospectus (Form S-4) for detailed financial data and risk factors not included in this 8-K.
- Confirm the final exchange ratio and cash consideration if the MiMedx stock price fluctuates significantly prior to closing (note: stock consideration is fixed at 0.4735 shares, but value may vary).
- Check for any announcements regarding "Superior Proposals" or changes in the Board's recommendation.